All sponsors

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. $1177.HK

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS44
PHASE 3 / 2-319
RECRUITING23
READOUTS ≤12 MONTHS18
READOUT SLIPPED >6 MO17%

Delay Index: of 23 active trials registered more than a year ago, 4 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →

Open Chia Tai Tianqing Pharmaceutical Group Co., Ltd. on the live radar map → 📅 $1177.HK readout calendar (.ics)
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
TQ05105 Tablet
NCT04944043
P1/2Active, not recruitingChronic Graft Versus Host Disease452023-06-30 (+12 mo)
Anlotinib hydrochloride capsules, Penpulimab injection
NCT05862337
P3RecruitingHepatocellular Carcinoma4802024-08
Anlotinib hydrochloride capsule
NCT04854668
P3Active, not recruitingMetastatic Colorectal Cancer7482024-12-31
6.0 mg/kg of TQB2102 for injection
NCT06198751
P2Active, not recruitingBreast Cancer1042025-05-08 (+4 mo)
TQB3616 capsule
NCT05365178
P3Active, not recruitingHR-positive, HER2-negative Breast Neoplasms4322025-07-02 (+13 mo)
TQB3909 Tablets + Azacitidine
NCT07011186
P1/2RecruitingMyeloid Malignancy1382025-10
TQA3605 tablets
NCT06150014
P1/2Active, not recruitingChronic Hepatitis b882025-12
TQA3334 Tablet
NCT06706310
P2Active, not recruitingChronic Hepatitis B1162025-12-07
TQB3702 tablets+Chemotherapy regimen
NCT06566586
P2RecruitingB-cell Lymphoma802026-03
TQB2825 injection +R-CHOP regimen
NCT06829771
P1/2RecruitingDiffuse Large B Cell Lymphoma902026-05 (+2 mo)
TQB2916 injection + doxorubicin hydrochloride for injection
NCT06500091
P2Not yet recruitingSoft Tissue Sarcoma; Melanoma542026-06
TQB3616 capsule+Fulvestrant Injection
NCT06702618
P2Active, not recruitingBreast Cancer332026-06 (+1 mo)
TQB2450 injection + Chemotherapy
NCT05913089
P2RecruitingNon Small Cell Lung Cancer582026-06
D-1553 Tablet
NCT06300177
P3RecruitingNon Small Cell Lung Cancer5222026-10
TQB3616 capsules, Letrozole, Anastrozole, Tamoxifen
NCT05780567
P3Active, not recruitingBreast Cancer19462026-12
TQB2930 for injection
NCT06202261
P1/2RecruitingMetastatic Breast Cancer; Recurrent Breast Cancer1542026-12
TQ05105 Tablets
NCT06122831
P1/2RecruitingMyelofibrosis922026-12
TQB3454 tablets
NCT05987358
P3Active, not recruitingBiliary Carcinoma1652026-12
TQB3702 Tablets
NCT06859931
P2Not yet recruitingSystemic Lupus Erythematosus1202026-12
AK105 Injection
NCT04344158
P3Active, not recruitingAdvanced Hepatocellular Carcinoma (HCC)6482026-12 (+29 mo)
TQB2102 for Injection
NCT06561607
P3Active, not recruitingBreast Cancer5422027-01
AL2846 Capsules
NCT06860971
P3RecruitingThyroid Cancer1442027-01
TQB6411 Injection
NCT07367516
P1/2RecruitingEsophageal Cancer1052027-02
TQC3721 Suspension for Inhalation
NCT07464587
P3RecruitingChronic Obstructive Pulmonary Disease8002027-02
TQC3721 Suspension for inhalation
NCT07147946
P3Not yet recruitingChronic Obstructive Pulmonary Disease6662027-03
TQB3473 Tablets
NCT06900920
P3RecruitingPrimary Immune Thrombocytopenia1992027-03
TQB3201 tablets
NCT07172126
P1/2Not yet recruitingMetastatic Castration-resistant Prostate Cancer2912027-04
Angiotensin II Injection
NCT06351150
P3RecruitingVasodilatory Shock2142027-06
TQD3524
NCT07512596
P2RecruitingHospital-acquired Bacterial Pneumonia/Ventilator-associated Bacterial Pneumonia482027-07
TQB3473 Tablets
NCT07083739
P2Not yet recruitingPrimary Immune Thrombocytopenia3202027-09
TQH3906 capsule
NCT07509892
P2RecruitingSystemic Lupus Erythematosus1982027-11
TQ05105 tablets
NCT06300320
P2RecruitingChronic Graft Versus Host Disease652027-11 (+25 mo)
LM-108 injection
NCT06821503
P1/2RecruitingAdvanced Pancreatic Cancer722027-12
Anlotinib hydrochloride capsule + TQB2450 injection
NCT06475599
P3Not yet recruitingEndometrial Cancer4202027-12
TQ-B3234 capsules
NCT07407803
P3RecruitingPlexiform Neurofibroma1772027-12
TQ05105 Tablets (Rovadicitinib Tablets)
NCT07551427
P2RecruitingMyelofibrosis512028-06
TQA3605 tablets
NCT07797231
P3Not yet recruitingChronic Hepatitis B9302028-09
TQB6411 for Injection
NCT07367529
P1/2RecruitingAdvanced Lung Cancer4652028-12
TQB2934 injection
NCT07569757
P3Not yet recruitingMultiple Myeloma2602028-12
Benmelstobart injection combined with Anlotinib hydrochloride capsule
NCT07548177
P2RecruitingAlveolar Soft Part Sarcoma332028-12
TQB3454 tablets
NCT07738679
P2Not yet recruitingAdvanced Solid Tumors1272028-12
TQB3126
NCT07697443
P1/2RecruitingBreast Cancer3002029-08
Rovadicitinib
NCT06682169
P3RecruitingGraft-versus-host Disease1822029-10
TQB3909 Tablets
NCT07753369
P3Not yet recruitingSmall Lymphocytic Lymppho; Relapsed/Refractory Chronic Lymphocytic Leukemia1282030-12